Chronic Kidney Disease Drugs Market size 2021 Worth US$ 16,222.7 Million by 2027 and Anticipate a Growth by 4.0% CAGR by Future Analysis, Business Overview and Estimation
SEATTLE, April 01, 2021, (PHARMIWEB) — Global Chronic Kidney Disease Drugs Market – Insights
Chronic kidney disease (CKD), also referred as chronic kidney failure, is the gradual loss of kidney function. The primary function of kidneys is to filter wastes and excess fluids from the blood, which are then excreted through urine. However, in advanced stage of chronic kidney disease, dangerous levels of fluids are formed in the body such as wastes and electrolytes. Moreover, its signs and symptoms are not visible until it has become substantially impaired.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1713
The supportive treatment of chronic kidney disease includes delaying the disease progression and kidney damage. Diseases and conditions such as type 1 or type 2 diabetes, high blood pressure, polycystic kidney disease, and recurrent kidney infection leads are major factors leading to chronic kidney disease. Moreover, diabetes, high blood pressure, smoking, obesity, etc. are some other factors responsible for chronic kidney disease. Management of the disease involves managing the co-morbidities such as blood pressure, diabetes medications, medications to lower cholesterol levels, and anemia treatment. Kidney dialysis and kidney transplant may become a necessity, as the condition becomes worse. There is no direct medication available for the treatment of chronic kidney disease. Chronic kidney diseases may trigger other healthcare issues such as cardiovascular diseases.
Market Dynamics
High prevalence of diseases leading to chronic kidney diseases are expected to foster growth of the chronic kidney disease drugs market
Growing prevalence of chronic disease such as kidney and high blood pressure are posing great risk at chronic kidney disease, which in turn, is expected to drive growth of the global chronic kidney disease drugs market during the forecast period. According to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. are estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease, which indicates the underlying market potential in chronic kidney disease drugs market. Moreover, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. According to the American Diabetes Association (ADA), in 2015, 30.3 million people in the U.S. were suffering from diabetes. According to CDC, in 2014, around 118,000 people in the U.S. started the treatment for end stage renal disease and as more people become aware of this condition, the number of people for treatment will increase. Therefore, these factors are expected to fuel the global chronic kidney disease drugs market over the forecast period.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1713
The global chronic kidney disease drugs market was valued at US$ 12,328.2 million in 2020 and is expected to witness a robust CAGR of 4.0% over the forecast period (2020 – 2027).
Figure 1. Global Chronic Kidney Disease Drugs Market Share (%), By Region, 2020
Initiatives taken by government organizations and manufacturers to increase awareness of chronic kidney disease is expected to boost the market growth over the forecast period
Governments of various countries and organizations are focused on working towards increasing the awareness of chronic kidney diseases. For instance, in May 2018, American Kidney Fund (AKF) launched comprehensive new kidney disease education portal. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). In March 2018, Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Moreover, in April 2018, CVS Health Corporation launched kidney disease initiative. In March 2018, Fresenius Medical North America (FMCNA) made a contribution of US$ 40,000 to Kidney School, world’s largest education program for people with chronic kidney disease.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/2PJRcC6
Market Dynamics- Restraints
However, delay in the diagnosis of chronic kidney disease is expected to restrain growth of the global chronic kidney disease drugs market over the forecast period.
Competitive Landscape
Key players operating in the global chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Patient Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- CKD Stages Treatment Options
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Product Launch/Approvals
- Collaboration & Agreements
- Pipeline Analysis
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Epidemiology
- Adherence Rate in the U.S.
- Global Chronic Kidney Disease Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
- Acute Kidney Injury Due to COVID-19
- Impact of COVID-19 on Clinical Trials and Drug Development
- Global Chronic Kidney Disease Drugs Market, By Drug Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- B-blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Loop Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Erythropoiesis-stimulating Agents (ESAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Phosphate Binders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Kidney Disease Drugs Market, By Patient Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Dialysis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Chronic Kidney Disease Drugs Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
Editor Details
-
Company:
- CDN Newswire
